Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy

Figures & data

Table 1 Trials Testing TKIs as Adjuvant Therapy

	ASSURE	S-TRAC	PROTECT	ATLAS	SORCE	EVEREST
	Sorafenib vs Sunitinib vs Placebo^Citation10,Citation11	Sunitinib vs Placebo^Citation12,Citation13	Pazopanib vs Placebo^Citation16,Citation17	Axitinib vs Placebo^Citation18	Sorafenib vs Placebo^Citation19	Everolimus vs Placebo^Citation20
N	1943	615	1538	724	1711	1545
Population	pT1b G3-4 N0 M0 or pT2-4 N0 M0 or pT any N+ M0	pT3 G2-4 N0 M0 or pT2-4 N0 M0 or pT any N+ M0	pT2 G3-4 N0 M0 or pT3-4 N0 M0 or pT any N1 M0	pT2-4 N0 M0 any or pT any N1 M0 any	pT1b-4 N0 M0 or pT any N1 M0	pT1 G3-4 N0 or pT3a G1-2 pT3a G3-G4 pT4 G any N+
Duration of treatment	54 w	1 yrs	1 yrs	1–3 yrs	3 vs 1 yrs	54 w
Primary Endpoint	DFS	DFS	DFS	DFS	DFS	RFS
DFS	HR 0.97 (0.8–1.17) HR 1.02 (0.85–1.23)	HR 0.761 (0.594–0.975)	HR 0.94 (0.77–1.14)	HR 0.87 (0.66–1.147)	HR 1.01 (0.82–1.23) HR 0.94 (0.77–1.14)	HR 0.85 (0.72–1)
OS	HR 0.98 (0.75–1.28) HR 1.17 (0.9–1.52)	HR 0.92 (0.66–1.28)	HR 1.0 (0.8–1.26)	-	HR 1.06 (0.82–1.38) HR 0.92 (0.71–1.20)	HR 0.90 (0.71–1.13)

Abbreviations: N, number of patients; w, weeks; yrs, years; DFS, disease-free survival; RFS, relapse-free survival; OS, overall survival; HR, hazard ratio.

Table 2 Ongoing Trials Testing IO in the Adjuvant Setting

	IMmotion010	CHECKMATE 914	RAMPART	LITESPARK-022	PROSPER
	NCT03024996^Citation29	NCT03138512^Citation30	NCT03288532^Citation31	NCT03142334^Citation32	NCT03055013^Citation44
Phase	III	III	III	III	III
Treatment arms	Atezolizumab vs placebo	Nivolumab +/- ipilimumab vs placebo	Durvalumab +/- tremelimumab vs observation	Pembrolizumab + placebo vs pembrolizumab + belzutifan	Nivolumab vs observation
Duration of treatment	1 year	6 months	1 year	1 year	1 month neoadjuvant; 9 months adjuvant
Histology	ccRCC	ccRCC	ccRCC nccRCC	ccRCC	ccRCC nccRCC
Primary endpoint	DFS	DFS	DFS	DFS	DFS

Abbreviations: ccRCC, clear cell renal cell carcinoma; nccRCC, non-clear cell renal cell carcinoma; DFS, disease-free survival.

Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, Phase 3 trial. Lancet. 2016;387(10032):2008–2016. doi:10.1016/S0140-6736(16)00559-6

 PubMed Web of Science ®Google Scholar

Haas NB, Manola J, Dutcher JP, et al. Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial. JAMA Oncol. 2017;3(9):1249. doi:10.1001/jamaoncol.2017.0076

 PubMed Web of Science ®Google Scholar

Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246–2254. doi:10.1056/NEJMoa1611406

 PubMed Web of Science ®Google Scholar

Motzer RJ, Ravaud A, Patard JJ, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol. 2018;73(1):62–68. doi:10.1016/j.eururo.2017.09.008

 PubMed Web of Science ®Google Scholar

Motzer RJ, Haas NB, Donskov F, et al. Randomized Phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. JCO. 2017;35(35):3916–3923. doi:10.1200/JCO.2017.73.5324

 PubMed Web of Science ®Google Scholar

Motzer RJ, Russo P, Haas N, et al. Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the Phase 3 PROTECT trial. Eur Urol. 2021;79(3):334–338. doi:10.1016/j.eururo.2020.12.029

 PubMed Web of Science ®Google Scholar

Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol. 2018;29(12):2371–2378. doi:10.1093/annonc/mdy454

 PubMed Web of Science ®Google Scholar

Eisen T, Frangou E, Oza B, et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized Phase III intergroup trial. JCO. 2020;38(34):4064–4075. doi:10.1200/JCO.20.01800

 PubMed Web of Science ®Google Scholar

Ryan CW, Tangen C, Heath EI, et al. EVEREST: everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249). JCO. 2022;40(17_suppl):LBA4500. doi:10.1200/JCO.2022.40.17_suppl.LBA4500

 Web of Science ®Google Scholar

Uzzo R, Bex A, Rini BI, et al. A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010). JCO. 2017;35(15_suppl):TPS4598. doi:10.1200/JCO.2017.35.15_suppl.TPS4598

 Web of Science ®Google Scholar

Bex A, Russo P, Tomita Y, et al. A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914). JCO. 2020;38(15_suppl):TPS5099. doi:10.1200/JCO.2020.38.15_suppl.TPS5099

 Google Scholar

Oza B, Frangou E, Smith B, et al. RAMPART: a phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemp Clin Trials. 2021;108:106482. doi:10.1016/j.cct.2021.106482

 PubMed Web of Science ®Google Scholar

Choueiri TK, Bedke J, Karam JA, et al. LITESPARK-022: a phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC). JCO. 2022;40(16_suppl):TPS4602. doi:10.1200/JCO.2022.40.16_suppl.TPS4602

 Web of Science ®Google Scholar

Harshman LC, Puligandla M, Haas NB, et al. PROSPER: a phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). JCO. 2019;37(7_suppl):TPS684. doi:10.1200/JCO.2019.37.7_suppl.TPS684

 Web of Science ®Google Scholar